Latest Briefings

Acquisition agreements during Covid-19

Given the ongoing impact of the Covid-19 pandemic, it is timely for us to look closely at material adverse change clauses in the context of a business acquisition.

Capital market trends and expectations for 2021

It has certainly been a profound start to a new decade thus far, and after the events of 2020, what have we noticed in terms of new stock exchange listing trends and what do we anticipate for this current calendar year?

The new how: thriving on change

The world is changing. At lightning-fast speed. This white paper, prepared as part of The Lawyer’s Smarter Working Week, looks at the main drivers for change in more detail and how you can prepare for ‘change3’.



Macfarlanes leads as Novartis moves HQ to London

Macfarlanes is advising on Novartis’s HQ move to White City, as the Swiss drugs giant sets its sights on joining a cluster of life sciences companies in West London. Novartis’s 600 HQ staff will relocate from Frimley in Surrey to the WestWorks building on the White City Place campus within the UK’s “golden triangle” bioscience hub […]


Hogan Lovells wins the top role for Novartis in $9bn pharma deal

Hogan Lovells and Cravath Swaine & Moore have won the top roles on Novartis’ $9bn purchase of Chicago-based gene therapy company AveXis. The deal, in which the Swiss pharmaceutical giant is offering $218 per share for AveXis, is being led by Hogan Lovells Washington DC-based corporate transactions partner Joseph Gilligan who is advising Novartis. He is working alongside New […]


A&O, Osborne Clarke and Proskauer Rose advise on $1.7bn Novartis deal

Allen & Overy (A&O), Osborne Clarke (OC) and Proskauer Rose have taken mandates advising on the $1.7bn (£1bn) sale of Swiss pharmaceutical giant Novartis’ transfusion diagnostics unit to Spanish plasma therapies company Grifols. Barcelona-headquartered Grifols will acquire the transfusion diagnostics unit of Novartis for US$1,675bn (£1,04bn). The assets include medical products and technology, as well […]


Novartis unveils panel designed to build ‘long-term partnerships’

Novartis has announced the results of its first panel review since the company’s $40bn takeover of Alcon, with three magic circle firms – Allen & Overy, Freshfields Bruckhaus Deringer and Linklaters – securing spots on the global roster along with two US firms. Pharma company Novartis’s new panel, called the legal preferred firm programme, is […]

Find legal roles

Make your next move with The Lawyer Careers. Search and apply for thousands of vacancies, or receive email alerts for new roles when they go live. Whether you're looking at private practice, in-house legal or an exciting business support role, you'll find your future here.

Search vacancies